Annual General Meeting Approves Dividend Proposal
Merck KGaA, Darmstadt, Germany, a leading science and technology company, held its 25th Annual General Meeting today. The company made use of the possibilities afforded by the German legislator in view of the coronavirus pandemic and conducted the shareholders’ meeting virtually.
The Annual General Meeting approved the actions of the Executive Board and the Supervisory Board of Merck KGaA, Darmstadt, Germany, for fiscal 2019 by a large majority and approved all of the resolutions on the agenda, including the proposed dividend of € 1.30 per share, an increase of € 0.05 over the previous year.
Around 1,000 users followed the live transmission via the Internet. When the resolutions were voted on, around 89.7 million shares were represented, corresponding to 69.38% of the approximately 129.2 million shares issued. The details of the voting results can be found at www.emdgroup.com/agm.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany, generated sales of € 16.2 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Merck KGaA, Darmstadt, Germany, has acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform technology, known as the “Breez™”.